By performing in vitro kinase assays we found in papilloma producing 308 mouse keratinocytes that okadaic acid elevated activities of extracellular signalregulated kinase (ERK) 1/2, c-Jun N-terminal kinases (JNKs) and p38 mitogen-activated protein kinases (MAPKs). This okadaic acid mediated activation of MAP kinases correlated with increased AP-1 binding to a consensus TPA responsive element (TRE) and elevated TRE dependent transcription. To determine the role of p38 MAP kinases in these processes we employed the speci®c p38 MAP kinase inhibitor SB 203580. Using orthophosphate labeling we showed a decrease in phosphorylation of MAPK activated protein kinase-2 (MAPKAP-K2) indicating reduced activity of p38 MAPKs utilizing this kinase as substrate. In contrast, we found that SB 203580 raised activities of ERK-1/2 and JNKs. Electrophoretic mobility shift assays revealed an increase in TRE binding activity in response to SB 203580 most likely resulting from increased expression of the major TRE binding components JunD and FosB as indicated by Western blot analyses. Increased TRE DNA binding failed to lead to increased transactivation correlating with the inability of SB 203580 to increase phosphorylation of these AP-1 proteins. These data indicate that SB 203580 sensitive p38 MAP kinases are not involved in okadaic acid mediated increases in TRE DNA binding and transactivation.
Introduction
Okadaic acid (OA) is a polyether compound of a C 38 fatty acid and is produced by certain dino¯agellates which concentrate in marine sponges and shell®sh. It is the major toxic component responsible for diarrhetic shell®sh poisoning (Tachibana et al., 1981; Murata et al., 1982) . Okadaic acid inhibits the serine-threonine phosphatases 1 (PP-1), 2A (PP-2A) (Bialojan and Takai, 1988 ) and 3 (PP-3) (Honkanen et al., 1991) by binding to their catalytic subunit and leads to the accumulation of hyperphosphorylated proteins (Haystead et al., 1989; Sassa et al., 1989) . Okadaic acid is also a potent tumor promoter in mouse skin initiated with 7, 12 dimethylbenz [a] anthracene (DMBA) (Suganuma et al., 1988) .
Several lines of experimental evidence suggest the activator protein 1 complex (AP-1) as critical component in epidermal tumor development in mouse skin and indicate that okadaic acid and other tumor promoters may elicit their tumor promoting capacity through activation of this complex. Most of these studies have been performed in the JB6 system which consists of tumor promoter sensitive and tumor promoter resistant cell lines. In this system, AP-1 activity has been found to be elevated in variants representing various stages of tumor promotion (Dong et al., 1995) . The hypothesis that increased AP-1 activity directly correlates with tumor promotion is further supported by the ®nding that acquisition of the tumor promoter resistant phenotype is associated with a loss of responsiveness to tumor promoter induced AP-1 activation (Bernstein et al., 1989) . Similar observations have been made in vivo in mouse skin where epidermal tumor development is accompanied by progressively increased AP-1 expression and transactivation (Yuspa, 1998) . Decreasing AP-1 activity or blocking AP-1 activation with`anti-tumor promoters' such as glucocorticoids, retinoids (Dong et al., 1994; Li et al., 1996; Huang et al., 1997) , aspirin and aspirin-like salicylates (Dong et al., 1997a) , or (7)-epigallocatechin gallate (EGCG) and thea¯avins (Dong et al., 1997b) , or dominant negative AP-1 mutants such as the dominant negative c-Jun mutant TAM 67 (Dong et al., 1994 (Dong et al., , 1997c Li et al., 1996) correlates with inhibition of tumor promoter induced transformation and tumor development. On the other hand overexpression of AP-1 leads to increased neoplastic transformation and constitutively high levels of AP-1 have been correlated with malignant conversion from papillomas to squamous cell carcinomas (Domann et al., 1994; Yuspa, 1998) .
AP-1 (Karin et al., 1997 ) is a transcription factor complex which is formed by members of the two protein families Jun and Fos. There are three dierent Jun proteins: c-Jun, JunB and JunD and four dierent Fos proteins: c-Fos, FosB, Fra-1 and Fra-2. These proteins possess leucine zipper domains through which they form homo-or heterodimers. Whereas Jun proteins are able to dimerize with each member of the AP-1 family, Fos proteins require a Jun protein as dimerization partner to bind to their respective DNA sequences. These DNA sequences named TPA responsive elements (TRE) after their ability to confer responsiveness to the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) are located in the promoter region of a number of dierent genes modulating their expression.
AP-1 activity is regulated at various levels including transcriptional and post-transcriptional mechanisms leading to increased AP-1 expression and posttranslational modi®cations such as phosphorylation and oxidation/reduction altering DNA binding anity and transactivation potential. Since DNA binding anity and transactivation potential are dierent for the various AP-1 proteins, AP-1 activity is also determined by its composition. AP-1 composition on the other hand is dependent not only on the sequence of the actual TRE but also on the sequence of adjacent bases (Ryseck and Bravo, 1991) .
Mitogen-activated protein kinases (MAPKs) have been identi®ed as important regulators of transcription factor activity thus translating extracellular signals into alterations of gene expression enabling cells to react to changes in their environment. There are dierent subtypes of MAPKs: the extracellular signal-regulated kinases (ERKs) and the stress activated kinases (SAPKs) comprising the c-Jun N-terminal kinases (JNKs) and the p38 mitogen-activated protein kinases (p38 MAPKs). Each group consists of several members. ERK and JNK (=SAPK1) each have two members, ERK-1 and ERK-2, which are also referred to as p44 and p42 MAPK, and p54 and p46 JNK. There are ®ve dierent p38 MAPKs, p38 (=SAPK 2a), p38 b (=SAPK 2b), p38 b2, p38 g (=SAPK 3/ERK-6) and SAPK 4. ERKs are predominantly stimulated by mitogens and hormones inducing either proliferation and cell growth or dierentiation (Marshall, 1995) whereas SAPKs are considered part of stress response pathways activated by cellular stress like heat or osmotic shock, radiation and pro-in¯ammatory cytokines mediating inhibition of proliferation or cell death (Xia et al., 1995) .
Recently we found that in papilloma producing 308 mouse keratinocytes okadaic acid mediated increases in AP-1 DNA binding and TRE dependent transactivation correlated with elevated activity of MAP kinases. The purpose of the following study was to de®ne the role of p38 MAP kinases in these eects of okadaic acid on AP-1 more closely by blocking its activity through use of the speci®c p38 MAP kinase inhibitor SB 203580 (Lee et al., 1994; Cuenda et al., 1995) . Such studies might advance our understanding of the complex process of tumor development and could help to develop molecular and pharmacological tools to manipulate neoplastic cell growth.
Results
SB 203580 activates ERK-1/2 and JNK and dierentially regulates p38 MAPK activity Previously we reported that in papilloma producing 308 mouse keratinocytes okadaic acid increased AP-1 binding to a consensus TPA-responsive element (Rosenberger and Bowden, 1996) and elevated TRE dependent transactivation. This increased AP-1 activity correlated with activation of the MAP kinases ERK-1/ 2, JNK and p38 MAPK, and ERK-1/2 activation appeared to play a critical role in okadaic acid mediated eects on this transcription factor complex (Rosenberger et al., 1999) . Various other studies implying p38 MAP kinase in AP-1 regulation (Hazzalin et al., 1996 (Hazzalin et al., , 1997 suggest that p38 MAP kinase may also be involved in okadaic acid induced AP-1 activation. To test this hypothesis we used SB 203580, a pyridinyl-imidazole compound described as speci®c inhibitor of this enzyme (Lee et al., 1994; Cuenda et al., 1995) , in an attempt to block p38 MAP kinase activation. To assure that under the experimental conditions used, SB 203580 inhibited p38 MAPK and to con®rm its speci®city we treated exponentially growing 308 cells with this inhibitor (or the solvent dimethyl sulfoxide, DMSO) for 1 h prior to the addition of 100 ng/ml okadaic acid (or DMSO). Crude cellular extracts were prepared and analysed for MAP kinase activity. p38 MAP kinase activity was determined by examining the extent of phosphorylation of its speci®c substrate MAPKAP kinase-2 using orthophosphate labeling. ERK-1/2 and JNK activities were investigated by Western blot analyses using phospho-speci®c antibodies to detect their phosphorylated, activated forms. To test whether the dierential regulation of the MAP kinases ERK-1/2, JNK and p38 MAP kinase aected okadaic acid mediated AP-1 activation we analysed AP-1 DNA binding and transactivation in response to SB 203580. To achieve this goal we ®rst performed electrophoretic mobility shift assays of crude nuclear extracts of exponentially growing 308 cells which had been pretreated with the inhibitor for 1 h prior to the addition of 100 ng/ml okadaic acid. At 4, 6 and 12 h TRE binding activity was analysed using a radiolabeled oligonucleotide of the human collagenase promoter including the TRE. The results are presented in Figure  3 . 308 cells showed basal TRE binding activity which was signi®cantly increased by okadaic acid. This okadaic acid mediated increase in TRE DNA binding activity was further elevated by SB 203580. Increased TRE DNA binding activity was already detectable at 4 h and gradually increased further at 6 and 12 h. The speci®city of the DNA-protein complex was determined by competition experiments in which varying amounts of unlabeled oligonucleotide were added to the binding reaction. Formation of the DNA-protein complex was abolished by the oligonucleotide containing the TRE element but not by a control oligonucleotide in which the core sequence is mutated (data not shown).
To test whether elevated TRE DNA binding activity leads to increased TRE dependent transactivation, we transiently transfected 308 cells with a luciferase reporter construct driven by the region 774 to +63 of the human collagenase gene containing a TRE element. After pretreatment with SB 203580 for 1 h, we treated the transfected cells for various times with 100 ng/ml okadaic acid. Crude cellular extracts were prepared and assayed for luciferase activity. The results shown in Figure 4 represent fold induction of okadaic acid treated samples over their respective DMSO controls. Consistent with our DNA binding data okadaic acid treatment resulted in increased TRE Figure 2 SB 203580 activates ERK-1/2 and JNK and dierentially regulates p38 MAPK activity. Exponentially growing 308 cells were pretreated with 20 mM p38 MAPK inhibitor SB 203580 or the solvent dimethyl sulfoxide (DMSO) for 1 h and treated with 100 ng/ml okadaic acid (OA) or DMSO. At indicated times cells were lysed and 40 mg of total protein were analysed by Western blot using 1 : 1000 dilutions of phosphospeci®c antibodies (a: ERK-1/2, b: JNK, c: p38 MAPK). Horseradish peroxidase conjugated goat anti-rabbit IgG (1 : 40 000) was used as secondary antibody. Antigen/antibody complexes were visualized by chemiluminescence Electrophoretic mobility shift assay of crude nuclear extracts (5 mg) of exponentially growing 308 using a radiolabeled TRE oligonucleotide. Cells pretreated with 20 mM SB 203580 or the solvent dimethyl sulfoxide (DMSO) for 1 h and treated with 100 ng/ml okadaic acid (OA) or DMSO dependent transactivation. The level of induction was 1.9+0.5-fold at 4 h, 4.7+0.4-fold at 6 h and 15.2+4.2-fold at 12 h. However, in contrast to our TRE DNA binding data, treatment with SB 203580 did not further elevate TRE dependent transactivation.
SB 203580 increases steady state protein levels of JunD and FosB
Previous results identi®ed increased expression of AP-1 proteins as a principal mechanism of okadaic acid elevated TRE DNA binding (Rosenberger and Bowden, 1996) . To test whether the observed additional increase in AP-1 DNA binding activity in response to SB 203580 was due to a similar mechanism we studied steady state levels of AP-1 proteins of exponentially growing 308 cells treated with 100 ng/ml okadaic acid for various time points with or without prior treatment with SB 203580. We focused on the AP-1 proteins JunD and FosB since these two members have been identi®ed as main components binding to the TRE oligonucleotide used in our experiments (Rosenberger et al., 1999) . As shown in Figure 5 okadaic acid increased amounts of JunD and FosB are further elevated due to treatment with SB 203580 at 4 and 6 h. For FosB the SB203580 mediated increase is also observed at 12 h whereas JunD levels are slightly decreased.
SB 203580 does not alter okadaic acid elevated phosphorylation of JunD and FosB
AP-1 activity is regulated by post-translational modi®cations such as phosphorylation. In the case of JunD and FosB this mechanism of regulation is only poorly understood. However, there is experimental evidence correlating increased phosphorylation of these two AP-1 proteins and increased transactivation capacity (Wang et al., 1996; Skinner et al., 1997) . To test the hypothesis that TRE dependent transactivation is not increased in response to SB 203580 due to a lack of phosphorylation, we performed orthophosphate labeling studies. Exponentially growing 308, pretreated with SB 203580, and then treated for 6 h with okadaic acid were labeled with orthophosphate and the extents of phosphorylation of immunoprecipitated JunD and FosB were determined. As shown in Figure 6 okadaic acid increased the phosphorylation of JunD and FosB. The amounts of phosphorylated proteins in cells pretreated with SB 203580 were unaected.
Discussion
SB 203580 belongs to a group of pyridinyl-imidazole compounds which have been described as potent and highly speci®c inhibitors of p38 MAP kinases. They bind in the ATP pocket of p38 MAP kinases and block their intrinsic ATPase activity (Lee et al., 1994; Cuenda et al., 1995) . Binding to ERK-1/2 and JNKs could not be detected and even at high concentrations activities of these kinases have not been found to be aected. Consistent with these reports we were able to show that SB 203580 decreased the phosphorylation of MAPKAP kinase-2 indicating a decrease in the activity of p38 MAP kinases eectively using this enzyme as substrate. Surprisingly, we found that inhibition of p38 MAP kinases correlated with increased activity of ERK-1/2 and JNK and modulated phosphorylation of p38 MAP kinases suggesting closely regulated cross talk and feedback mechanisms between the dierent signal transduction pathways involving MAP kinases. This hypothesis is further supported by Sheikh-Hamad et al., (1998) who reported that in osmotically stressed cells inhibition 6 SB 203580 has no eect on okadaic acid elevated phosphorylation of JunD and FosB. Exponentially growing 308 cells were pretreated with 20 mM SB 203580 or the solvent dimethyl sulfoxide (DMSO) for 1 h and treated with 100 ng/ml okadaic acid (OA) or DMSO. During the last hour of treatment they were labeled with 100 mCi/ml 32 P-orthophosphate. At 6 h cells were lysed and equal counts were immunoprecipitated with antibodies speci®c for JunD or FosB. The immunoprecipitates were analysed by SDS-polyacrylamide gel electrophoresis. The results shown are representative of three independent experiments p38 MAPK and AP-1 expression, binding and transactivation SF Rosenberger et al of p38 MAP kinase upregulates JNK activity. A similar interconnection between the dierent MAP kinase cascades has been demonstrated by Ludwig et al. (1998) who found that arsenite induced activation of ERK-1/2 is mediated by p38 MAP kinase. The ability of MAP kinases to regulate the activity of their family members may be explained by their eects on activating kinases and/or deactivating phosphatases as documented by the ®nding that p38 MAP kinase is involved in inhibition of the ERK-1/2 activating kinase MEK-1 in response to high concentrations of pervanadate (Daum et al., 1998) . p38 MAP kinase also mediates hyperosmolarity induced expression of the MAP kinase phosphatase MKP-1 (Schliess et al., 1998) , which dephosphorylates and inactivates ERK-1/ 2, JNK and p38 MAP kinase (Chu et al., 1996) .
Eects of SB 203580 on MAP kinase activating kinases or deactivating phosphatases may also explain the modulation of p38 MAP kinase phosphorylation. We found that phosphorylation of a subtype of p38 MAP kinases is decreased whereas a faster migrating form shows increased phosphorylation.
Since the development of SB 203580, p38 MAP kinases have been identi®ed and characterized which are resistant to SB 203580 inhibition. These p38 MAP kinases named p38g or SAPK 3 and SAPK 4 also dier at least to some extent in their stimulus dependent activation and their substrate speci®city e.g. SAPK 3 and SAPK 4 phosphorylate predominantly transcription factors such as ATF-2 and Elk-1 and are far less eective in phosphorylating MAPKAP kinase-2 Goedert et al., 1997; Kumar et al., 1997) . It is possible that the p38 MAP kinase form with decreased phosphorylation represents the SB 203580 sensitive group of p38 whereas the p38 MAP kinase form with increased phosphorylation represents the resistant group of p38. This hypothesis is consistent with our preliminary ®nding that while SB 203580 decreases MAPKAP kinase-2 phosphorylation it increases p38 MAP kinase mediated phosphorylation of Elk-1 (data not shown). Further evidence comes from a report by Hazzalin et al. (1997) who documented elevated activity of the p38 MAP kinase activator MKK6 without an increase in MAKAP kinase-2 phosphorylation.
Phosphorylation of p38 MAP kinases could also be modulated through direct interaction of the inhibitor with the enzyme as indicated by the identi®cation of a possible second binding site outside the ATP pocket with currently unknown function (Tong et al., 1998) . More experiments will be necessary to test these possibilities.
Okadaic acid increases TRE DNA binding activity by stimulating the expression of JunD and FosB which have been identi®ed as main AP-1 components binding to a human collagenase TRE oligonucleotide. TRE DNA binding activity as well as JunD and FosB protein levels are further elevated in response to SB 203580. These ®ndings suggest that the MAP kinases activated by SB 203580 are involved in inducing JunD and FosB expression potentially by either directly or indirectly phosphorylating and activating transcription factors which regulate their transcription. Our previous observation that inhibition of ERK-1/2 with the MEK-1/2 inhibitor PD 98059 does not decrease okadaic acid elevated JunD and FosB protein levels (Rosenberger et al., 1999) suggest JNK as primary regulator of expression of these AP-1 proteins.
Although SB 203580 mimicked okadaic acid by increasing AP-1 expression and DNA binding activity, it did not match okadaic acid eects on AP-1 transactivation indicating its inability to induce further modi®cations of prebound AP-1 proteins. A requirement of such modi®cations for increased AP-1 transactivation has also been discussed by who reported that overexpression of the AP-1 protein c-Jun was not sucient for elevated AP-1 activity. Phosphorylation analyses revealed that okadaic acid treatment resulted in an increase in overall phosphorylation of JunD and FosB. The amount of phosphorylated proteins in cells pretreated with SB 203580 was unaected.
These data suggest a potential role of increased JunD and FosB phosphorylation in okadaic acid induced AP-1 transactivation. In contrast to c-Jun, whose regulation by phosphorylation is well documented, less is known about phosphorylation changes modulating the activity of JunD and FosB. Nikolakaki et al. (1993) reported that glycogen synthase kinase 3 phosphorylates JunD in a region proximal to its DNA binding domain and attenuates its DNA binding capacity. In contrast, the ®nding that serum induced phosphorylation of JunD does not aect its ability to bind DNA provides evidence that phosphorylation may also regulate the transactivation potential of this factor (Wang et al., 1996) . In a similar fashion, phosphorylation of several serine residues in the Cterminal transactivation domain of FosB has been shown to increase its transcriptional activity (Skinner et al., 1997) .
Previously we have found that inhibition of ERK-1/ 2 by PD 98059 blocked JunD and FosB phosphorylation and totally abrogated AP-1 transactivation indicating that these eects are mediated by ERK-1/ 2. The fact that SB 203580 induced increases in ERK-1/2 activity did not result in increased phosphorylation and AP-1 transactivation suggest that ERK-1/2 is a necessary but not sucient component in okadaic acid signal transduction leading to AP-1 activation. An essential role for this MAP kinase in AP-1 activation has also been suggested by Huang et al. (1998) . In a tumor promoter resistant variant of JB6 mouse epidermal cells they found that shortage of ERK-2 is responsible for resistance to TPA and EGF induced AP-1 activation and transformation and that ERK-2 expression restores these responses.
In conclusion, these results using the p38 MAP kinase inhibitor SB 203580 together with our previous observations using the MEK-1/2 inhibitor PD 98059 indicate that in papilloma producing 308 mouse keratinocytes, okadaic acid stimulates AP-1 activity by two dierent mechanisms which appear to be mediated by independent signal transduction pathways. Okadaic acid increases TRE DNA binding activity by stimulating expression of the AP-1 proteins JunD and FosB. These eects of okadaic acid occur independently from okadaic acid mediated activation of ERK-1/2 and SB 203580 sensitive p38 MAP kinases and appear to involve JNKs. Increased TRE DNA binding activity does not necessarily result in increased TRE dependent transactivation. Further modi®cations of the pre-existing AP-1 proteins are necessary. These p38 MAPK and AP-1 expression, binding and transactivation SF Rosenberger et al modi®cations most likely in form of phosphorylation are mediated through an increase in ERK-1/2 activity which is required but apparently not sucient for increased transactivation. These data are consistent with a report by Gum et al. (1997) demonstrating a requirement for both ERK-1/2 and JNK in AP-1 mediated collagenase expression.
Materials and methods

Cell culture and treatment
The papilloma producing mouse keratinocytes 308 were kindly provided by SH Yuspa (Strickland et al., 1988) . The cells were maintained in minimal essential medium (MEM) supplemented with 7.5% fetal calf serum (FCS), 2.5% calf serum (CS) and 100 U/ml penicillin/streptomycin (all purchased from Gibco ± BRL) at 378C in a humidi®ed atmosphere containing 7.5% of CO 2 . For experiments, cells were grown to 75 ± 90% con¯uency. Before treatment cells were washed once with serum free MEM. Cells were treated with okadaic acid (sodium salt, LC Laboratories) dissolved in dimethyl sulfoxide (DMSO) added to serum free MEM to a ®nal concentration of 100 ng/ml; controls were treated with equivalent amounts of DMSO (0.01% v/v). In indicated experiments, prior to the addition of okadaic acid/DMSO, cells were pretreated for 1 h with 20 mM SB 203580 (4-(4-Fluorophenyl)-2-(4-methylsul®nylphenyl)-5-(4-pyridyl)1H-imidazole, generously provided by Smith Kline Beecham), a speci®c inhibitor of p38 MAP kinase dissolved as 20 mM stock in DMSO; controls were treated with DMSO (0.1% v/v).
Transactivation analysis
308 cells were transiently transfected using DOTAP liposomal transfection reagent (N-[1-(2, 3-dioleoyloxy) propyl]-N, N, Ntrimethylammonium methylsulfate, Boehringer Mannheim) with a luciferase reporter construct driven by the region 774 to +63 of the human collagenase gene containing a TRE element (kindly provided by P Brown and LM Yang). 1.5610 5 cells were seeded in a 6-well plate and transfected after 24 h under serum free conditions with 5 mg DNA. After 12 h, cells were transferred to serum containing MEM. After another 12 h the cells were treated. At various times, cells were lysed in 1% Triton X-100, 25 mM glycylglycine, 15 mM MgSO 4 , 4 mM EGTA, 1 mM DTT and protein concentration was determined with Bio-Rad D C reagent (Bio-Rad Laboratories). 180 ml of assay buer (25 mM glycylglycine, 15 mM K 3 PO 4 , 15 mM MgSO 4 , 4 mM EGTA, 1 mM DTT, 2 mM ATP) were added to 40 mg of protein and the luminescence reaction was initiated in a Monolight 2010 luminometer with the injection of 100 ml 0.2 mM d-luciferin (in 25 mM glycylglycine, 15 mM MgSO 4 , 4 mM EGTA, 2 mM DTT). After 2 s, emission was integrated over a 10 s interval and expressed as relative light units (RLU).
Isolation of cellular protein
Cells were lysed in 20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerolphosphate, 1 mM sodium vanadate, 1 mg/ml leupeptin, 1 mM phenylmethylsulfonyl uoride and protein concentration was determined with Bio-Rad D C reagent (Bio-Rad Laboratories)
Isolation of nuclear protein
Cells were rinsed once with phosphate buered saline (PBS) and once with buer A (10 mM HEPES (N- [2-hydroxyethyl] piperazine-N'-[2-ethanesulfonic acid]) pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM DTT). Cells were scraped, pelleted by centrifugation at 1000 r.p.m. for 2 min at 48C and lysed in buer A containing 0.1% Nonidet P-40 for 30 min at 48C. Crude nuclear protein extracts were prepared by the method of Dignam et al. (1983) . Nuclei were pelleted by centrifugation at 10 000 r.p.m. for 15 min at 48C, resuspended in buer C (20 mM HEPES pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl¯uoride, 0.5 mM DTT) and incubated for 15 min at 48C. The extracts were centrifuged at 10 000 r.p.m. for 15 min at 48C, and the supernatant was diluted 1 : 6 with buer D (20 mM HEPES pH 7.9, 20% glycerol, 100 mM KCl, 0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl¯uoride, 0.5 mM DTT). The protein concentrations of the extracts were determined with Bio-Rad reagent (BioRad Laboratories).
Electrophoretic mobility shift assay
Oligonucleotide probes were labeled by incorporation of 32 PdCTP (NEN) into the 5' overhangs of the annealed oligonucleotide of the human collagenase TRE 5'-aaagcaTGAGTCAgacacct-3' with Klenow DNA polymerase. The oligonucleotide binding assay was performed by mixing 1610 5 c.p.m. probe with 5 mg nuclear protein extract in the presence of 2 mg poly(dI-dC)×poly(dI-dC) (Pharmacia LKB Biotechnology) and gel shift buer (10 mM Tris pH 7.5, 50 mM NaCl, 1 mM MgCl 2 , 0.5 mM DTT, 4% glycerol) at room temperature for 30 min. DNA binding complexes were resolved by gel electrophoresis on 5% polyacrylamide/ 16TBE (Tris-borate electrophoresis buer: 89 mM Tris, 89 mM boric acid, 2 mM EDTA) gels. The gels were dried and exposed to Kodak X-AR ®lm at 7808C for 2 ± 96 h using an intensifying screen.
Western analysis
20 mg of crude nuclear extract or 40 mg of crude cellular extract were boiled in SDS sample buer (60 mM Tris pH 6.8, 2% SDS, 5% b-mercaptoethanol, 10% glycerol, 0.001% bromphenol blue) and resolved on 12.5% SDSpolyacrylamide gels. The proteins were transferred to a PVDF nylon membrane (Millipore Immobilon P) by electroblotting at 50 V at 48C for 12 ± 16 h using a transfer buer containing 25 mM Tris, 190 mM glycine and 20% methanol. The membrane was blocked in 5% nonfat dry milk in TBST (10 mM Tris pH 8.0, 150 mM NaCl, 0.05% Tween-20) at room temperature for 1 h. Primary antibody was diluted 1 : 1000 (phospho-speci®c ERK-1/2, phospho-speci®c JNK, phospho-speci®c p38 MAPK) or 1 : 3000 (JunD, FosB) in dry milk/TBST and added (antibodies: Santa Cruz Biotechnology, phospho-speci®c antibodies: New England BioLabs). The membrane was incubated at room temperature for 1 h and then washed three times with TBST. Horseradish peroxidase conjugated goat anti-rabbit IgG was added at a dilution of 1 : 40 000 in 5% dry milk/TBST. The membrane was incubated at room temperature for 1 h and then washed three times with TBST. Antigen-antibody complexes were detected using ECL TM Western blotting detection reagents (Amersham Life Science) according to manufacturer's instructions.
Orthophosphate labeling
7610
5 cells were seeded in a 10 cm plate. After 48 h, cells were treated and during the last hour of the treatment following incubation in phosphate free MEM for 1 h, labeled with 100 mCi/ml 32 P-orthophosphate. Cells were lysed in RIPA buer (50 mM Tris pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1% sodium deoxycholate). The lysates were precleared with 50% protein A sepharose beads in TENN buer (50 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40) for 10 min at 48C. Equal counts 1610 c.p.m were incubated with 1 : 100 dilutions of anti MAPKAP kinase-2 (Upstate Biotechnology) or AP-1 antibodies with gentle rocking overnight at 48C. Protein A sepharose beads were added and the mixture was rotated at 48C for 2 h, washed three times in SNNTE buer (50 mM Tris pH 7.4, 0.5 M NaCl, 5 mM EDTA, 1% NP-40, 5% sucrose) and twice in RIPA buer. Samples were boiled in SDS sample buer and analysed on 12.5% SDS-polyacrylamide gels.
